Rodman David Malcom 4

What Happened Rodman David Malcom, Chief Medical Officer of Mineralys Therapeutics (MLYS), exercised options to acquire 417 shares and disposed of those 417 shares on March 17, 2026. The exercise price was $15.44 per share (total cash cost $6,438) and the open-market sale was at $25.65 per share (gross proceeds $10,696). The transactions were executed under a Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-03-17.
• Exercise: 417 shares acquired at $15.44 each (total $6,438).
• Sale: 417 shares sold in open market at $25.65 each (gross proceeds $10,696).
• A separate derivative disposition of 417 shares at $0.00 is also reported (part of the exercise/conversion reporting).
• Footnotes: F1 — transactions effected under a 10b5-1 plan adopted Oct 6, 2025; F2 — option vesting schedule (25% after 1 year, then monthly over 36 months).
• Shares owned after the transaction: not specified in the filing.
• Filing timeliness: reported with the same report date (no late filing indicated).

Context Because the exercise and sale occurred on the same day, this functions like a cashless exercise (exercised options and sold the resulting shares). Sales by insiders can be routine (including plan-directed sales); the 10b5-1 plan note indicates the trades followed a pre-established trading arrangement.